Shanghai Fudan-Zhangjiang Enrolls First Patient in U.S. Phase II Study for Port Wine Stain Treatment

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a leading biopharmaceutical company based in China, has announced the enrollment of the first patient in a Phase II clinical study for its hemoporfin photo-dynamic therapy (PDT) in the United States. The study is focused on treating port wine stain (PWS), a common vascular skin birthmark. This second-generation photosensitizer is the first of its kind globally for PWS treatment and is known for its stable compound structure and low phototoxicity. Its approval for marketing in China as a Category 1 drug in 2017 has significantly contributed to the company’s revenue growth, which reached 36.17% year-on-year during the first half of 2024.-Fineline Info & Tech